Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Resverlogix and Hepalink Start Taiwan/China Trial of CVD/Diabetes Treatment

publication date: Jul 10, 2017
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Canada's Resverlogix has begun a Phase III trial in Taiwan of its lead drug, apabetalone, in high-risk patients with cardiovascular disease and type 2 diabetes. Two years ago, Shenzhen Hepalink, a heparin company, acquired greater China rights to the drug in a $440 million deal. Hepalink will underwrite the costs of the greater China trial, and its start triggers a $1 million payment to Resverlogix. The trial will be expanded to include China. The Taiwan-China arm is part of Resverlogix's global apabetalone trial, which will eventually enroll 2,400 patients. More details....

Stock Symbols: (TSX: RVX) (SHZ: 002399)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login